Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Gastroenterology ; 119(5): 1219-27, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11054379

ABSTRACT

BACKGROUND & AIMS: Assay of altered DNA exfoliated into stool represents an intriguing approach to screen for colorectal neoplasia, but multiple markers must be targeted because of genetic heterogeneity. We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without. METHODS: Freezer-archived stools were analyzed in blinded fashion from 22 patients with colorectal cancer, 11 with adenomas > or =1 cm, and 28 with endoscopically normal colons. After isolation of human DNA from stool by sequence-specific hybrid capture, assay targets included point mutations at any of 15 sites on K-ras, p53, and APC genes; Bat-26, a microsatellite instability marker; and highly amplifiable DNA. RESULTS: Analyzable human DNA was recovered from all stools. Sensitivity was 91% (95% confidence interval, 71%-99%) for cancer and 82% (48%-98%) for adenomas > or =1 cm with a specificity of 93% (76%-99%). Excluding K-ras from the panel, sensitivities for cancer were unchanged but decreased slightly for adenomas to 73% (39%-94%), while specificity increased to 100% (88%-100%). CONCLUSIONS: Assay of altered DNA holds promise as a stool screening approach for colorectal neoplasia. Larger clinical investigations are indicated.


Subject(s)
Adenocarcinoma/diagnosis , Adenoma/diagnosis , Colonic Neoplasms/diagnosis , DNA, Neoplasm/analysis , Feces/chemistry , Rectal Neoplasms/diagnosis , Adenocarcinoma/genetics , Adenoma/genetics , Adult , Aged , Aged, 80 and over , Colonic Neoplasms/genetics , DNA/analysis , DNA/chemistry , Feasibility Studies , Female , Humans , Male , Middle Aged , Pilot Projects , Rectal Neoplasms/genetics , Reference Values , Sensitivity and Specificity , Single-Blind Method
2.
Hum Mol Genet ; 6(3): 337-47, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9147636

ABSTRACT

As more mutations are identified in genes of known sequence, there is a crucial need in the areas of medical genetics and genome analysis for rapid, accurate and cost-effective methods of mutation detection. We have developed a multiplex allele-specific diagnostic assay (MASDA) for analysis of large numbers of samples (> 500) simultaneously for a large number of known mutations (> 100) in a single assay. MASDA utilizes oligonucleotide hybridization to interrogate DNA sequences. Multiplex DNA samples are immobilized on a solid support and a single hybridization is performed with a pool of allele-specific oligonucleotide (ASO) probes. Any probes complementary to specific mutations present in a given sample are in effect affinity purified from the pool by the target DNA. Sequence-specific band patterns (fingerprints), generated by chemical or enzymatic sequencing of the bound ASO(s), easily identify the specific mutation(s). Using this design, in a single diagnostic assay, we tested samples for 66 cystic fibrosis (CF) mutations, 14 beta-thalassemia mutations, two sickle cell anemia (SCA) mutations, three Tay-Sachs mutations, eight Gaucher mutations, four mutations in Canavan disease, four mutations in Fanconi anemia, and five mutations in BRCA1. Each mutation was correctly identified. Finally, in a blinded study of 106 of these mutations in > 500 patients, all mutations were properly identified. There were no false positives or false negatives. The MASDA assay is capable of detecting point mutations as well as small insertion or deletion mutations. This technology is amenable to automation and is suitable for immediate utilization for high-throughput genetic diagnostics in clinical and research laboratories.


Subject(s)
DNA Mutational Analysis/methods , Genetic Diseases, Inborn/diagnosis , Genetic Testing/methods , Mutation , Alleles , DNA Primers , DNA Probes , Electrophoresis, Polyacrylamide Gel , Genetic Diseases, Inborn/genetics , Genetic Testing/instrumentation , Humans , Nucleic Acid Hybridization , Polymerase Chain Reaction
3.
Prenat Diagn ; 16(4): 289-98, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8734801

ABSTRACT

Three major methods have been described for the isolation of fetal cells from maternal blood: fluorescence-activated cell sorting (FACS), immunomagnetic beads, and magnetic-activated cell sorting (MACS). To date, no study has directly compared fetal cell recovery using each of these methods. Here we describe our system using a "model' male fetal cell mixed into female peripheral blood mononuclear cells. Fetal cell yields and purities were assayed by a quantitative polymerase chain reaction (qPCR) using chromosomes Y- and 7-specific sequences. Fetal cell recovery was investigated by selection of CD71+ cells or depletion of CD45+ cells. Our data demonstrated variation in fetal cell recovery for all methods tested, although CD71+ selection by FACS gave the best and most consistent results.


Subject(s)
Cell Separation/methods , Fetus/cytology , Pregnancy/blood , Prenatal Diagnosis/methods , Antigens, CD/analysis , Antigens, Differentiation, B-Lymphocyte/analysis , Female , Fetus/physiology , Flow Cytometry/methods , Humans , Immunomagnetic Separation , In Vitro Techniques , Leukocyte Common Antigens/analysis , Male , Polymerase Chain Reaction , Receptors, Transferrin , Reproducibility of Results
4.
Hum Mol Genet ; 2(2): 153-8, 1993 Feb.
Article in English | MEDLINE | ID: mdl-7684636

ABSTRACT

The identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has led to the identification of more than 225 presumed disease-causing mutations at the locus. The diagnosis of cystic fibrosis or the carrier state by direct DNA analysis is hindered by this large number. A practical assay must be able to detect enough mutations to achieve clinically significant sensitivity. The use of allele-specific oligonucleotide probes is the most promising of the available methods. However, to date this has generally involved tedious probe-by-probe hybridizations, due to variations in the oligonucleotides' denaturation temperatures caused by differences in their G-C base-pair content. We have developed a rapid, cost-effective assay that simultaneously detects 12 CFTR mutations after multiplex polymerase-chain-reaction amplification of genomic DNA. The test may be readily extended to detect additional mutations at minimal increase in the cost per test or the turnaround time. We improve specificity and avoid the need for individual hybridizations by the use of tetramethylammonium chloride to virtually eliminate the effects of G-C differences. Coupled with non-invasive sample-collection methods, this is an immediately practical assay for cystic fibrosis. More generally, it will serve as a model for the development of diagnostic tests in other genetic disorders involving complex mutation analysis.


Subject(s)
Cystic Fibrosis/diagnosis , DNA Mutational Analysis/methods , Membrane Proteins/genetics , Oligonucleotide Probes , Cystic Fibrosis/genetics , Cystic Fibrosis/prevention & control , Cystic Fibrosis Transmembrane Conductance Regulator , Genetic Carrier Screening , Genetic Testing , Humans , Polymerase Chain Reaction , Sensitivity and Specificity
5.
Hum Mol Genet ; 2(2): 159-63, 1993 Feb.
Article in English | MEDLINE | ID: mdl-7684637

ABSTRACT

Traditionally, DNA used for PCR-based diagnostic analysis has originated from white cells fractionated from whole blood. Although this method yields substantial quantities of DNA, there are some drawbacks to the procedure, including the inconvenience of drawing blood, risk of exposure to blood-borne pathogens, liquid sample handling, and the somewhat involved extraction procedure. Alternatively, DNA for genetic diagnosis has been derived from finger stick blood samples, hair roots, cheek scrapings, and urine samples. Oral saline rinses have also been used extensively as a means of collecting buccal epithelial cells as a DNA source. However, this method still requires liquid sample handling. Herein, we present our results involving the rapid extraction of DNA from buccal cells collected on cytology brushes and swabs for use in PCR reactions, specifically the multiplex amplification of 5 exons within the CFTR gene. The quality of DNA isolated from buccal cells, collected in this manner, has been sufficient to reproducibly support multiplex amplification. Cheek cell samples and the DNA prepared from them as described here are highly stable. The success rate of PCR amplification on DNA prepared from buccal cells is 99%. In a blind study comparing the analysis of 12 mutations responsible for cystic fibrosis in multiplex products amplified with DNA from both blood and buccal cell samples from 464 individuals, there was 100% correlation of results for blood and cheek cell DNA, validating the use of DNA extracted from cheek cells collected on cytology brushes for use in genetic testing.


Subject(s)
DNA Mutational Analysis , Membrane Proteins/genetics , Mouth Mucosa/cytology , Polymerase Chain Reaction , Base Sequence , Cheek , Cystic Fibrosis/diagnosis , Cystic Fibrosis/genetics , Cystic Fibrosis/prevention & control , Cystic Fibrosis Transmembrane Conductance Regulator , DNA/blood , DNA Mutational Analysis/instrumentation , Feasibility Studies , Genetic Testing , Humans , Molecular Sequence Data , Single-Blind Method , Specimen Handling
SELECTION OF CITATIONS
SEARCH DETAIL
...